As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives ...

CEO Albert Bourla told investors Tuesday morning that he is “cautiously optimistic” about working with Robert F. Kennedy Jr., ...

Few CEOs know the double-edged nature of dealing with US President Donald Trump as viscerally as Pfizer’s Albert Bourla. In his first term, Trump championed the $18 billion Operation Warp Speed ...

As well as, falling in tandem with the release of Pfizer’s annual earnings report, which reflected revenues of $63.6 billion. In the announcement, Bourla stated: “I’m excited for what’s ...

Its high debt load remained a cause of investor concern for the entire year, and as a result, CEO Albert Bourla’s turnaround strategy is now a key part of Pfizer Inc. (NYSE:PFE)’s hypothesis.

Starboard last year took a $1 billion stake in Pfizer, looking to turn the pharma around after alleged severe shortcomings by its current leadership. But Bloomberg reports it has missed the deadline ...

(Reuters) -U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive Officer Albert Bourla said at the ...

Pfizer's CEO Albert Bourla said that he's had dinner with Trump's health secretary pick, RFK Jr. Bourla said he was "cautiously optimistic" about the new administration. Kennedy is now close to ...

(Reuters) -U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive Officer Albert Bourla said at the ...